You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Syncope following ‘pill-in-the-pocket’ treatment of atrial fibrillation with propafenone plus quinidine
  1. Harry W Daniell
  1. Correspondence to Harry W Daniell, Department of Family Practice, University of California at Davis Medical School, 2626 Edith Ave., Suite A, Redding, CA 96001, USA; hwdaniell{at}aol.com

http://dx.doi.org/10.1136/heartjnl-2011-300672

Statistics from Altmetric.com

    To the Editor The important report by Alboni et al1 not only documents risks associated with the use of propafenone during ‘pill-in-the-pocket’ (PIP) therapy for paroxysmal atrial fibrillation (PAF) but also hints at techniques by which its use may be made safer. The primary metabolism of propafenone occurs through hepatic CYP4502D6 isoenzyme activity, resulting in differences between the safety of propafenone administered intravenously and orally.

    CYP2D6 activity may also be strongly inhibited by other commonly prescribed medications, including quinidine, amiodarone, cimetidine, erythromycin and most selective serotonin re-uptake inhibitor antidepressants, …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.